Review article: Methotrexate in gastroenterology - Dangerous villain or simply misunderstood?

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 6, 1996, Pages 851-858

  Tang, H ^a   Neuberger, J ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ARTICLE; BILIARY CIRRHOSIS; COST BENEFIT ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERANCE; ENTERITIS; HUMAN; LIVER TOXICITY; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS;

EID: 0029821008     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.70244000.x     Document Type: Article

References (64)

1. Coe RO, Bull FE. Cirrhosis associated with methotrexate treatment of psoriasis. J Am Med Assoc 1968; 206: 1515-20.
2. Nair MG, Baugh CM. Synthesis and biological evaluation of poly-glutamyl derivatives of methotrexate. Biochemistry 1973; 12: 3923-7.
3. Kremer JM, Galivan J, Streckfuss A, et al. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Arthritis Rheum 1986; 29: 832-5.
4. Weber BI, Tanyer G, Poplack DG, et al Transient acute hepatotoxicity of high dose methotrexate treatment during childhood. Natl Cancer Inst Monograph 1987; 5: 207-12.
5. Mclntosh S, Davidson DC, O'Brien RT, et al. Methotrexate hepatotoxicity in children with leukaemia. J Pediatr 1977; 90: 1019-21.
6. Hutter RVP, Shipkey FH, Tam CTC, et al. Hepatic fibrosis in children with acute leukaemia: A complication of therapy. Cancer 1960; 13: 288-307.
7. Fries JF, Singh G. Lenert L, et al. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1611-9.
8. Evans WE, Pratt CB. Effect of pleural effusion on high dose methotrexate kinetics. Clin Pharmacol Ther 1987; 23: 68-72.
9. Carson CW, Cannon GW, Egger MJ, et al. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987; 21: 186-195.
10. Kamel OW, Van de Rijn M, Weisslm, et al. Reversible lymphoma associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328: 1317-21.
11. Fried M, Kalro J, Ilardi C, et al. Hepatocellular carcinoma in a long term survivor of acute lymphocytic leukaemia. Cancer 1987; 60: 2548-52.
12. Ruymann FB, Mosijczuk A, Sayers RJ. Hepatoma in a child with methotrexate induced hepatic fibrosis. J Am Med Assoc 1977; 238: 2631-3.
13. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy. Acta Pathol Microbiol Scand Sect A 1977; 85: 511-8.
14. Weinstein GD, Roenigk H, Maibac HI, et al. Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973; 108: 36-42.
15. Zachariae H, Kragbelle K, Sogaard H. Methotrexate induced liver cirrhosis: Studies including serial liver biopsies during continued treatment. Br J Dermatol 1980; 102: 407-12.
16. Walker Am, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low dose methotrexate for rheumatoid arthritis. Arthritís Rheum 1993; 36: 329-35.
17. Roenigk H, Auerbach R, Maibach H, et al. Methotrexate guidelines: revised. J Am Acad Dermatol 1982; 6: 145-55.
18. Clegg DO, Furst DE, Tolman KG, et al. Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis. J Rheumatol 1989; 16: 1123-6.
19. Kujala GA, Shamma'a JM, Chang WL, et al. Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate. Arthritis Rheum 1990; 33: 1037-41.
20. Gilbert SC, Klintmalm G, Menter A, et al. Methotrexate induced cirrhosis requiring liver transplantation in three patients with psoriasis. Arch Intern Med 1990; 150: 889-91.
21. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176-82.
22. Zachariae H. Methotrexate side effect. Br J Dermatol 1990; 122 (Suppl. 36): 127-33.
23. Epstein EH, Croft JR. Cirrhosis following methotrexate administration for psoriasis. Arch Dermatol 1969; 100: 531-4.
24. Muller SA, Farrow GM, Martalock DL. Cirrhosis caused by methotrexate in the treatment of psoriasis. Arch Dermatol 1969; 100: 523-30.
25. Nyfors A, Poulsen H. Liver biopsies from psoriatics related to methotrexate therapy: Findings in 123 consecutive non-methotrexate treated patients. Acta Pathol Microbiol Scand Sect A 1976; 84: 253-61.
26. Ashton RE, Millward-Sadler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982; 79: 229-32.
27. Robinson AK, Baughman RD, Auerbach R, et al. Methotrexate hepatotoxicity in psoríasis. Consideration of liver biopsies at regular intervals. Arch Dermatol 1980; 116: 413-5.
28. Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989; 125: 1218-24.
29. Roenigk H, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145-56.
30. Reese LT, Grisham JW, Aach RD, et al. Effects of methotrexate on the liver in psoriasis. J Invest Dermatol 1974; 62: 597-602.
31. Zachariae H, Søgaard H. Methotrexate-induced liver cirrhosis. Dermatologica 1987; 175: 178-82.
32. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of Glasgow; British Association of Dermatogists. Guidelines for management of patients with psoriasis. Br Med J 1991; 303: 829-35.
33. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis: effects on disease activity in a multicentre prospective study. J Rheumatol 1991; 18: 334-8.
34. Combe B, Pope RM. Fischbach M, et al. Interleukin-2 rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol 1985; 59: 520-8.
35. Weinblatt ME, Trentham DE, Fraser DA, et al Long term prospective trial of low dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 167-75.
36. Olsen NJ, Callahan LF, Pincus T. Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1987; 30: 481-8.
37. Cream JJ, Pole DS. The effect of methotrexate and hydroxyurea on neutrophil chemotaxis. Br J Dermatol 1980; 102: 557-63.
38. Health and Public Policy Committee, American College of Physicians. Methotrexate in rheumatoid arthritis. Ann Intern Med 1987; 107: 418-9.
39. Kremer JM, Alarcon GS, Lightfoot RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-28.
40. Bjorkman DJ, Hammond EH, Lee RG, et al. Hepatic ultra-structure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988; 31: 1465-72.
41. Bjorkman DJ, Boschert M, Tolman KG, et al. The effect of long term methotrexate therapy on hepatic fibrosis in rheumatoid arthritis. Arthritis Rheum 1993; 36: 1697-1701.
42. Whiting-O'Keefe QE, Fye KH, Sack KD, Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711-6.
43. Kremer JM. Lee RG, Tolman G. Liver histology in rheumatoid arthritis patients receiving long term methotrexate therapy. Arthritis Rheum 1989; 32: 121-7.
44. Kremer JM. Long term prospective sequential biopsies in patients with rheumatoid arthritis on wekly oral methotrexate. Arthritis Rheum 1990; 33 (Suppl. 9): S40. (Abstract.)
45. Aponte J, Petrelli M. Liver histology in methotrexate treated rheumatoid arthritis patients: repeat biopsies after the development of fibrosis. Arthritis Rheum 1988; 31: S116.
46. Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84 month update. Arthritis Rheum 1992; 35: 129-37.
47. Tishler M, Caspi D, Halperin Z, et al. A prospective analysis of liver biopsies in rheumatoid arthritis patients receiving long term methotrexate therapy. Rheumatol Int 1992; 12 (1): 39-41.
48. Brick JE, Moreland LW, Al-Kawas F, et al. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin Arthritis Rheum 1989; 19: 31-44.
49. Chandran G, Ahern MJ, Hall PM, et al. Cirrhosis in patients with rheumatoid arthritis receiving low dose methotrexate. Br J Rheumatol 1994; 33: 981-4.
50. Phillips CA, Cera PJ, Mangan TF, et al. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992; 19: 229-33.
51. Bergquist SR, Felson DT, Prashker MJ, et al. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1995; 38: 326-33.
52. Kaplan MM, Knox TA, Arora S. Primary biliary cirrhosis treated with low-dose oral pulse methotrexate. Ann Intern Med 1988; 109: 429-31.
53. Miller LC, Dinarello C. Methotrexate inhibits IL-1 activity. Arthritis Rheum 1986; 29: S86.
54. Kaplan MM, Knox TA. Treatment of primary cirrhosis with low-dose weekly methotrexate. Gastroenterology 1991; 101: 1332-8.
55. Bergasa N, Hoofnagle J, Axiotis C, et al. Oral methotrexate for primary biliary cirrhosis: preliminary report. Gastroenterology 1991; 100: A720. (Abstract.)
56. Buscher HP, Zietzschmann Y, Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding in sufficiently to ursodeoxycholic acid alone. J Hepatol 1993; 18: 9-14.
57. Schaffner F, Bach N, Thung SN. Effect of long term, low-dose methotrexate therapy for primary biliary cirrhosis on liver biopsy morphology. Hepatology 1996; 23: 230 (Abstract).
58. Kaplan M. Methotrexate after five years in primary biliary cirrhosis. Gastroenterology 1991; 102: A829. (Abstract.)
59. Kaplan M, Knox T. Methotrexate for biliary cirrhosis. Gastroenterology 1992; 102: 1824. (Letter.)
60. Kozarek RA. Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with reflactory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6.
61. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's Disease. N Engl J Med 1995; 332: 292-7.
62. Alvarez F, Dullavis J, O'Brien J. The role of methrexate therapy in the management of patients with cyclosporin A-resistant inflammatory bowel disease. Gastroenterology 1996; 110: A853. (Abstract.)
63. Gohkale R, Kirschner BS. Methotrexate therapy in children with severe Crohn's Disease: preliminary results. Gastroenterology 1996; 110: A916. (Abstract.)
64. Zenjari T, Lemann M, Mesnard B, et al. Methotrexate in Crohn's Disease: long term efficacy and toxicity. Gastroenterology 1996; 110: A1053. (Abstract.)